vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $188.3M, roughly 1.1× BRC Group Holdings, Inc.). BRC Group Holdings, Inc. runs the higher net margin — 47.9% vs 8.3%, a 39.7% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs -21.9%). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs -15.4%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
COLL vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $188.3M |
| Net Profit | $17.0M | $90.3M |
| Gross Margin | 62.5% | 79.5% |
| Operating Margin | 29.6% | 32.3% |
| Net Margin | 8.3% | 47.9% |
| Revenue YoY | 12.9% | -21.9% |
| Net Profit YoY | 35.3% | 1710.8% |
| EPS (diluted) | $0.48 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $205.4M | $188.3M | ||
| Q3 25 | $209.4M | $215.3M | ||
| Q2 25 | $188.0M | $188.2M | ||
| Q1 25 | $177.8M | $197.2M | ||
| Q4 24 | $181.9M | $241.0M | ||
| Q3 24 | $159.3M | $225.5M | ||
| Q2 24 | $145.3M | $256.0M | ||
| Q1 24 | $144.9M | $263.4M |
| Q4 25 | $17.0M | $90.3M | ||
| Q3 25 | $31.5M | $91.1M | ||
| Q2 25 | $12.0M | $139.5M | ||
| Q1 25 | $2.4M | $-10.0M | ||
| Q4 24 | $12.5M | $-5.6M | ||
| Q3 24 | $9.3M | $-284.4M | ||
| Q2 24 | $19.6M | $-433.6M | ||
| Q1 24 | $27.7M | $-49.2M |
| Q4 25 | 62.5% | 79.5% | ||
| Q3 25 | 61.7% | 83.7% | ||
| Q2 25 | 57.7% | 81.3% | ||
| Q1 25 | 54.8% | 81.4% | ||
| Q4 24 | 54.0% | 79.8% | ||
| Q3 24 | 60.8% | 82.1% | ||
| Q2 24 | 62.5% | 84.5% | ||
| Q1 24 | 63.1% | 85.3% |
| Q4 25 | 29.6% | 32.3% | ||
| Q3 25 | 29.7% | 30.4% | ||
| Q2 25 | 18.7% | 5.7% | ||
| Q1 25 | 12.2% | -31.2% | ||
| Q4 24 | 20.9% | -69.2% | ||
| Q3 24 | 21.9% | -36.4% | ||
| Q2 24 | 32.7% | -90.8% | ||
| Q1 24 | 34.1% | -6.1% |
| Q4 25 | 8.3% | 47.9% | ||
| Q3 25 | 15.0% | 42.3% | ||
| Q2 25 | 6.4% | 74.1% | ||
| Q1 25 | 1.4% | -5.1% | ||
| Q4 24 | 6.9% | -2.3% | ||
| Q3 24 | 5.9% | -126.1% | ||
| Q2 24 | 13.5% | -169.4% | ||
| Q1 24 | 19.1% | -18.7% |
| Q4 25 | $0.48 | $2.78 | ||
| Q3 25 | $0.84 | $2.91 | ||
| Q2 25 | $0.34 | $4.50 | ||
| Q1 25 | $0.07 | $-0.39 | ||
| Q4 24 | $0.36 | $-0.01 | ||
| Q3 24 | $0.27 | $-9.39 | ||
| Q2 24 | $0.52 | $-14.35 | ||
| Q1 24 | $0.71 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $301.7M | $-171.5M |
| Total Assets | $1.7B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $386.7M | $226.6M | ||
| Q3 25 | $285.9M | $184.2M | ||
| Q2 25 | $222.2M | $267.4M | ||
| Q1 25 | $197.8M | $138.3M | ||
| Q4 24 | $162.8M | $146.9M | ||
| Q3 24 | $120.0M | $159.2M | ||
| Q2 24 | $271.6M | $236.9M | ||
| Q1 24 | $318.0M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $301.7M | $-171.5M | ||
| Q3 25 | $274.8M | $-260.5M | ||
| Q2 25 | $232.2M | $-351.7M | ||
| Q1 25 | $234.4M | $-496.8M | ||
| Q4 24 | $228.8M | $-488.2M | ||
| Q3 24 | $234.3M | $-497.6M | ||
| Q2 24 | $216.6M | $-218.3M | ||
| Q1 24 | $222.2M | $228.4M |
| Q4 25 | $1.7B | $1.7B | ||
| Q3 25 | $1.6B | $1.7B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.5B | ||
| Q4 24 | $1.7B | $1.8B | ||
| Q3 24 | $1.6B | $2.2B | ||
| Q2 24 | $1.1B | $3.2B | ||
| Q1 24 | $1.1B | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | $26.2M |
| Free Cash FlowOCF − Capex | $122.4M | — |
| FCF MarginFCF / Revenue | 59.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 7.25× | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $123.0M | $26.2M | ||
| Q3 25 | $78.4M | $-60.6M | ||
| Q2 25 | $72.4M | $-25.6M | ||
| Q1 25 | $55.4M | $184.0K | ||
| Q4 24 | $84.6M | $-2.7M | ||
| Q3 24 | $-9.0M | $19.5M | ||
| Q2 24 | $67.4M | $111.5M | ||
| Q1 24 | $61.9M | $135.4M |
| Q4 25 | $122.4M | — | ||
| Q3 25 | $78.3M | — | ||
| Q2 25 | $72.4M | — | ||
| Q1 25 | $54.6M | — | ||
| Q4 24 | $84.1M | — | ||
| Q3 24 | $-9.2M | — | ||
| Q2 24 | $67.1M | — | ||
| Q1 24 | $61.4M | — |
| Q4 25 | 59.6% | — | ||
| Q3 25 | 37.4% | — | ||
| Q2 25 | 38.5% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | 46.2% | — | ||
| Q3 24 | -5.8% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 42.3% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | 7.25× | 0.29× | ||
| Q3 25 | 2.49× | -0.66× | ||
| Q2 25 | 6.05× | -0.18× | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COLL
Segment breakdown not available.
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
